Glurenorm (Gliquidone)

Glurenorm is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient.

• As monotherapy in patients newly diagnosed with type 2 diabetes.
• In combination with metformin when glycemic control is not achieved with metformin alone.
• As adjunct to other oral antidiabetic agents such as thiazolidinediones.
• For patients who have demonstrated adequate pancreatic beta‑cell function.
• To assist in achieving individualized HbA1c targets as part of a comprehensive diabetes care plan.

The safety profile of Glurenorm includes a range of observed adverse reactions, which are generally categorized by frequency and severity.

Common

• Mild hypoglycemia, especially when meals are skipped or delayed.
• Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia.
• Skin reactions like rash or pruritus.
• Headache or dizziness.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including angioedema or anaphylaxis.
• Hepatotoxicity manifested by jaundice or elevated liver enzymes.
• Hematologic abnormalities such as leukopenia or thrombocytopenia.

Before initiating Glurenorm, clinicians should evaluate several clinical factors to minimize risks and ensure appropriate use.

• Assess renal and hepatic function, as impairment may increase drug exposure.
• Verify that the patient has sufficient endogenous insulin production.
• Use caution in elderly patients due to heightened hypoglycemia risk.
• Review history of cardiovascular disease, as sulfonylureas may affect cardiac outcomes.
• Counsel patients on recognizing and managing hypoglycemia symptoms.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.

Glurenorm can interact with other medicines, potentially altering its glucose‑lowering effect or increasing adverse events.

Avoid

• Concurrent use with other sulfonylureas or insulin, which may cause additive hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise gliquidone plasma levels.

Use with caution

• Beta‑blockers, which may mask hypoglycemia symptoms.
• Thiazide diuretics, which can impair glucose control.
• Anticoagulants such as warfarin, as glycemic changes may affect INR stability.
• NSAIDs, which may affect renal function and drug clearance.